My understanding of HER2+ is that it's generally considered a more aggressive cancer. Stage 1 HER2+ is early, but you also need to also consider the level of HER2+ positivity, if there is hormone positivity, and the grade (1,2 or 3) of cancer cells. Do you have a KI-67 score? That may help inform your next steps. Treatment is always a personal choice. For myself I never questioned going forward with cancer chemo targeted therapy treatment, as the attributes of the tumor I had suggested a poorer prognosis if I did nothing.

I was diagnosed with stage 1, HER2+ (positivity 3), hormone negative, grade 3 breast cancer post mastectomy in January 2023. The surgery was for multi-focal DCIS in my left breast and localized DCIS in my right breast (those were diagnosed in October 2022, so no chemo prior to surgery). Once the HER2+ tumor stage 1 was found I made the choice to be treated with Kadcyla (TDM1), a chemo targeted drug, emtasine bound with herceptin. I was supposed to have 17 rounds, but had to stop at 13 due to increased liver enzymes not in scope of what's considered reasonable. I continued to work fulltime through treatment with the exception of an infusion day every 3 weeks. I did struggle some with fatigue. It's now been over a year and half since treatment ended and I am doing very well.